Magenta Therapeutics EBIT

Magenta Therapeutics (MGTA) currently reports a EBIT of $-220M as of June 2026. That compares with $-130M in the prior-year period — down 67.9% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Magenta Therapeutics's EBIT history and peer comparisons.

Magenta Therapeutics's EBIT decreased from $-130M to $-220M — a 67.9% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Magenta Therapeutics's EBIT of $-220M is lower than the Healthcare sector average of $23B. That is roughly 101.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Magenta Therapeutics reported $-220M in EBIT as of June 2026. That compares with $-130M in the prior-year period — down 67.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-220M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Magenta Therapeutics, and consider following MGTA for alerts when major investors trade the stock.